ERCC1 and seminoma: Immunodetection for ERCC1, NF-κB, and TG2 markers was positive in 42%, 76% and 46% of the patient’s samples analyzed, respectively, and there were no statistically significant differences between seminoma and non-seminoma (Figures 1 A, B and C, Table-2).